sunitinib zentiva
zentiva italia s.r.l. - sunitinib - sunitinib
sunitinib dr. reddy's
dr. reddy s s.r.l. - sunitinib - sunitinib
sunitinib glenmark
glenmark arzneimittel gmbh - sunitinib - sunitinib
sutent 12.5 mg capsule rigide
pfizer ag - sunitinibum - capsule rigide - sunitinibum 12.5 mg ut sunitinibi malas, mannitolum, carmellosum natricum conexum, povidonum k 25, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 171, drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, e 171, pro capsula corresp. natrium 0.47 mg. - trattamento gastrointestinale tumori stromali possono, trattamento del tumore del rene, il trattamento di neuroendokrinem carcinoma pancreatico - synthetika
sutent 25 mg capsule rigide
pfizer ag - sunitinibum - capsule rigide - sunitinibum 25 mg ut sunitinibi malas, mannitolum, carmellosum natricum conexum, povidonum k 25, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 171, e 172 (flavum), e 172 (nigrum), drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, e 171, pro capsula corresp. natrium 0.36 mg. - trattamento gastrointestinale tumori stromali possono, trattamento del tumore del rene, il trattamento di neuroendokrinem carcinoma pancreatico - synthetika
sutent 50 mg capsule rigide
pfizer ag - sunitinibum - capsule rigide - sunitinibum 50 mg ut sunitinibi malas, mannitolum, carmellosum natricum conexum, povidonum k 25, magnesii stearas, kapselhülle: gelatina, e 172 (rubrum), e 171, e 172 (flavum), e 172 (nigrum), drucktinte: lacca, propylenglycolum, natrii hydroxidum, povidonum, e 171, pro capsula corresp. natrium 0.71 mg. - trattamento gastrointestinale tumori stromali possono, trattamento del tumore del rene, il trattamento di neuroendokrinem carcinoma pancreatico - synthetika
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenti antineoplastici - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
inlyta 1 mg compresse rivestite con film
pfizer ag - axitinibum - compresse rivestite con film - axitinibum 1 mg, cellulosum microcristallinum, lactosum monohydricum, carmellosum natricum conexum corresp. natrium 0.21 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum, triacetinum, e 171, e 172 (rubrum), pro compresso obducto corresp. lactosum monohydricum 33.60 mg. - carcinoma a cellule renali - synthetika
inlyta 5 mg compresse rivestite con film
pfizer ag - axitinibum - compresse rivestite con film - axitinibum 5 mg, cellulosum microcristallinum, lactosum monohydricum, carmellosum natricum conexum corresp. natrium 0.37 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum, triacetinum, e 171, e 172 (rubrum), pro compresso obducto corresp. lactosum monohydricum 58.8 mg. - carcinoma a cellule renali - synthetika
inlyta 3 mg compresse rivestite con film
pfizer ag - axitinibum - compresse rivestite con film - axitinibum 3 mg, cellulosum microcristallinum, lactosum monohydricum, carmellosum natricum conexum corresp. natrium 0.22 mg, magnesii stearas, Überzug: hypromellosum, lactosum monohydricum, triacetinum, e 171, e 172 (rubrum), pro compresso obducto corresp. lactosum monohydricum 35.30 mg. - carcinoma a cellule renali - synthetika